Abstract: The emergence and rapid proliferation of Coronavirus Disease-2019, throughout the past year, has put an unprecedented strain on the global schema of health infrastructure and health economy. The time-sensitive agenda of identifying the virus in humans and delivering a vaccine to the public constituted an effort to flatten the statistical curve of viral spread as it grew exponentially. At the forefront of this effort was an exigency of developing rapid and accurate diagnostic strategies. These have emerged in various forms over the past year—each with strengths and weaknesses. To date, they fall into three categories: (1) those isolating and replicating viral RNA in patient samples from the respiratory tract (Nucleic Acid Amplification Tests; NAATs), (2) those detecting the presence of viral proteins (Rapid Antigen Tests; RATs) and serology-based exams identifying antibodies to the virus in whole blood and serum. The latter vary in their detection of immunoglobulins of known prevalence in early-stage and late-stage infection. With this review, we delineate the categories of testing measures developed to date, analyze the efficacy of collecting patient specimens from diverse regions of the respiratory tract, and present the up and coming technologies which have made pathogen identification easier and more accessible to the public.

Keywords: COVID-19; NAAT; RT-PCR; Ct value; RT-LAMP; rapid antigen test; antibody test; point of care testing

1. Introduction

The illness now known as Coronavirus Disease-2019, or COVID-19, was first described in mid-December 2019 when the Wuhan health authorities detected a cluster of cases of atypical pneumonia [1]. As Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the cause of COVID-19, spread globally, the need for rapid, accurate diagnostic testing was recognized. In this review, we discuss the direct and indirect methods that are currently employed for diagnosis of SARS-CoV-2 infection. Although this virus is relatively new, a plethora of publications have appeared in the last year, and a comprehensive review of all available data is beyond the scope of this paper. We present a brief overview of the virus and available testing options.

2. Viral Structure

Coronaviruses are enveloped, positive-sense, single-stranded RNA viruses [2]. A part of the Coronaviridae family, Betacoronavirus genus, SARS-CoV-2 is the seventh coronavirus known to infect humans [3]. Understanding the structure and genomic architecture of the virus is important, as this is the basis of the targets for the various diagnostic tests. The SARS-CoV-2 virion is roughly spherical and 60–140 nm in diameter [4]. A viral membrane contains the spike (S) glycoprotein, giving the virus its characteristic corona or crown-like appearance [5]. The spike protein features two functional subunits [6]: S1, containing the receptor-binding domain (RBD) that mediates binding to the host cell surface receptor angiotensin-converting enzyme-2 (ACE2); and S2, which mediates membrane fusion.
(ACE-2), and S2, which is integral to the subsequent fusion between the viral and host cellular membranes [5]. Other structural proteins include the membrane (M) protein and envelope (E) protein, which create the ring-like structure, and the nucleocapsid (N) protein, which plays a role in successful host cell entry (Figure 1). Additionally, the N-protein is complexed to the single-strand RNA genome, approximately 30 kb in length [7]. The SARS-CoV-2 genome encodes proteases and an RNA-dependent RNA polymerase (RdRp) [6]. The 5′ terminus of the genome contains ORF1ab, which is the largest of all genes [6]. The 3′ terminus contains four structural proteins, S, E, M, N, and eight accessory proteins [6]. A diversity of targets are employed by different test manufacturers, mainly encompassing regions located in the open reading frame (ORF1), envelope (env), nucleocapsid (N), spike (S) and RNA-dependent RNA polymerase (RdRp) genes. However, mutations across these regions may impact diagnostic performance by affecting specific oligo-binding sites and affecting test sensitivity. Even though SARS-CoV-2 possesses proofreading capacity which makes transcription and replication less prone to mutations, mutational events still occur. Thus, continuous genomic monitoring and target (primer/probe) optimization is key for diagnostic performance.

![Figure 1. Structure of SARS-CoV-2 virus. A—Schematic of SARS-CoV-2 virion, B—Schematic of SARS-CoV-2 genome structure. Reprinted with permission from ref. [8]. Copyright 2021 American Society for Microbiology-Journals.](image)

### 3. Whom to Test

Throughout the pandemic, the populations who meet criteria for testing have evolved as the testing capacity has expanded. Initially, only patients with symptoms compatible with COVID-19 who had traveled to Wuhan, China, were eligible to be tested. As the pandemic progressed and local community transmission was recognized, rapid diagnosis of potentially SARS-CoV-2-infected individuals became crucial in order to cut off chains of transmission, and the requirement for travel was eliminated. As more diagnostic assays became available, screening of potentially exposed but asymptomatic patients became more widespread. Screening in facilities such as nursing homes and other communal living settings has become an indication for testing [9]. Other groups for whom screening of asymptomatic individuals has now been implemented include schools, travelers, healthcare workers, and those with potential exposure to individuals diagnosed with COVID-19 [10]. The Infectious Diseases Society of America (IDSA) has designed an algorithm to assist in the decision of whom to test that stresses the importance of testing symptomatic individuals and lists others who may meet criteria such as recently exposed or pre-procedural and testing available [11].

### 4. What Specimen to Collect

Nasopharyngeal (NP) swabs are the preferred specimen for direct detection of SARS-CoV-2 according to both the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) guidelines.
However, several significant barriers are associated with collection of NP swab specimens for SARS-CoV-2 detection, including the requirement for collection by a trained provider, the use of personal protective equipment (PPE) due to triggering of reflex cough/sneeze during collection, patient discomfort, and potential harm, including a case of a Cerebral Spinal Fluid (CSF) leak due to improper collection [11,12]. Additionally, supply chain disruption resulting in scarcity of the flocked swabs and transport media used for collection of NP specimens has been a concern, particularly during the pandemic surge. As a result, alternate upper respiratory tract specimen types have been evaluated such as anterior nares or nasal swabs. Pere et al. compared NP swabs and nasal swabs in 44 consecutive patients. They detected four false negatives in the nasal swab group (9.1%) and there were no additional positives found in the nasal swab group not detected in the NP swab group [13].

Saliva is another alternative specimen type that has been considered for SARS-CoV-2 diagnostic testing. Advantages of this specimen type include ease of collection, minimal patient discomfort, and improved safety for both patients and providers. As collection of saliva does not provoke a cough/sneeze reflex, guidelines do not require special provider PPE for aerosol exposure. Furthermore, since flocked collection swabs and transport media are not required, reliance on the material supply chain is minimized. In an initial proof of concept, To et al. collected saliva from known positive patients and demonstrated that SARS-CoV-2 could be detected in specimens collected from 11 of the 12 tested [14]. Wyllie et al. compared paired samples of saliva and NP swabs from 70 in-patients with a known diagnosis of COVID-19. At days 1–5 after diagnosis, more patients tested positive from saliva (81%) than NP specimens. (71%). Overall, viral load was higher in saliva than in the paired NP swab specimens (5.58 vs. 4.93 mean log copies per mL) [15]. Conversely, a study of paired NP and saliva samples from 91 patients found NP swab specimens to be slightly more sensitive in the first week and 20% more sensitive if collected in the second week of illness or later [16]. The suitability of saliva for detection of SARS-CoV-2 may reflect overall viral dynamics, since both upper respiratory tract contents as well as lower respiratory secretions driven by the mucociliary airway epithelium combine in the oral cavity. Of note, a recent study from Huang et al. demonstrated higher RNA expression of the ACE2 receptor and the TMPRSS2 internalization protease in epithelial cells of the glands and oral mucosae, which translated into a higher salivary viral burden [17]. Moreover, recent evidence provided by Savela et al. suggests that high-sensitivity saliva-based tests can detect the presence of SARS-CoV-2 earlier in the infection when compared to self-collected anterior-nares nasal swabs [18].

SARS-CoV-2 can also be detected in lower respiratory specimens, although reports from different investigators are contradictory regarding diagnostic sensitivity, perhaps influenced by stage of disease or other patient characteristics. Possible lower tract specimens include sputum, tracheal aspirates and bronchoalveolar lavage (BAL). Tracheal aspirates are much simpler to obtain in intubated patients; however, unlike BAL fluid, the viscosity of the specimens vary. However, BAL has the disadvantage of requiring an invasive procedure. Some studies have suggested that lower respiratory tract specimens may be persistently positive longer than upper tract specimens. In a case reported from Thailand, a patient whose NP and oropharyngeal swab specimens had twice tested negative was diagnosed by RT-PCR detection of SARS-CoV-2 in a bronchoalveolar lavage (BAL) specimen collected on hospital day 8 [19]. One potential explanation for this is that lower respiratory tract epithelial cells and pneumocytes have a higher density of ACE2 receptors that serve as the target for SARS-CoV-2 earlier in the infection when compared to self-collected anterior-nares nasal swabs [20,21].

Understanding SARS-CoV-2 viral dynamics in the respiratory system may help to better guide specimen collection. However, studies addressing SARS-CoV-2 tissue distribution and dynamics are still scarce. Viral loads are known to differ amongst sample types, being higher in respiratory samples at early stages of the disease. For example, a meta-analysis comparing 3442 respiratory samples, including 1299 nasopharyngeal swabs, 1083 oropharyngeal swabs and 1060 sputum samples, indicated that sputum (71% positive samples) was far more sensitive than oropharyngeal swabs (54%) or nasopharyngeal swabs (43%), although when stratified by time since onset of symptoms, sensitivity was diminished for all three specimens types the
later in the disease course the specimens were collected [22]. Interestingly, Hou et al. utilized reverse genetics to show a variable infectious gradient throughout the respiratory tract that parallels tissue expression of the ACE-2 receptor [23]. In addition, they assessed viral tropism and distribution in lungs from deceased COVID-19 patients, demonstrating a higher gradient of virus in the upper respiratory tract vs. the lower tract, and suggested that infection of type 2 pneumocytes in the alveolar region is seeded by aspiration of the virus in upper airway secretions [23]. A separate meta-analysis comparing different methodologies identified that pooled nasal and throat swabs gave the highest sensitivity of 97%, followed by nasal swabs (86%) and saliva (85%) and finally throat swabs alone (68%). Moreover, in a different meta-analysis by Weiss et al., it was found that SARS-CoV-2 PCRs remained positive longer in the lower respiratory tract (LRT) compared to the upper respiratory tract (URT), both in mild disease (5.7 days) and moderate–severe disease (5.9 days). In patients with mild disease, the viral load peaked on day 4 of illness with a maximum viral load of $6.61 \times 10^8$ viral copies/mL in the URT, as compared to the LRT, which peaked on day 6 at $2.69 \times 10^8$ copies/mL. In patients with moderate to severe disease, the URT viral load peaked at $4.60 \times 10^8$ copies/mL on day 8 as compared to the LRT with a peak of $3.45 \times 10^8$ copies/mL on day 11.

Once the site of sample collection has been determined, the next consideration is the collection device and transport conditions. Traditionally, samples collected for viral testing are transported in viral transport media (VTM), which contains a mix of Hanks balance salt solution, antibiotics, antifungals, and a PH indicator. At the onset of the pandemic, these were in short supply. Many centers tested using saline or phosphate buffered saline (PBS) as transport media and found these performed as well as VTM [24,25]. It is recommended that samples be stored at 2–80 °C and tested within 72 h, otherwise they should be frozen until they can be tested [10] in order to preserve nucleic acid stability and integrity.

5. Types of Diagnostic Testing
5.1. Nucleic Acid Amplification Tests (NAAT)

Detection of the presence of viral RNA using NAAT has become the mainstay of SARS-CoV-2 diagnosis with real-time polymerase chain reaction (RT-PCR) being the most common NAAT method currently employed [10]. RT-PCR involves several steps, the first being extraction of viral RNA from the collected specimens using silica or magnetic particle-based methods. Next, there is reverse transcription of the viral RNA to a single-stranded DNA copy (cDNA) using a reverse transcriptase enzyme. Finally, there is the amplification step where the extracted viral RNA is mixed with reagents containing the primers, probes and master mix and detection is obtained through a coupled fluorescent marker [26]. The first RT-qPCR for SARS-CoV-2 detection was developed by China’s Center for Disease Control and Prevention and was designed to detect the N and the ORF1ab genes [27]. Next, the Charite Institute developed a protocol incorporating primers targeting genes of the E, N, and RdRp [27]. In the U.S., the first RT-PCR protocol was developed by the CDC and targeted N1 and N2 [27]. Internationally, there are many different primers and probe sets available from the World Health Organization [28]. Vogels et al. compared seven primer sets and found they all had similar performance characteristics [29]. It is important to mention that, as specified by Corman et al., the performance varies for different targets across the viral genome, potentially affecting sensitivity and specificity [30].

In the U.S., multiple commercial assays are now marketed [31] and several assays are available as part of a test system that utilizes a single, self-contained, high-throughput instrument to perform all the PCR or other NAAT steps (Table 1). To address the urgent need for diagnostic test capacity, these tests were reviewed by the US Food and Drug Administration (FDA) through an emergency use authorization pathway. The early EUA process required companies to submit analytic sensitivity, limit of detection, along with cross-reactivity studies [32]. Initial studies submitted to the FDA were performed using contrived samples, not patient samples, and therefore clinical correlation was not performed. Consequently, determination of sensitivity and specificity against a clinical gold standard is not generally available for these assays [31].
Table 1. Comparative list of nucleic acid amplification tests for the detection of SARS CoV-2, by manufacturer, origin of specimen, target gene, sensitivity, specificity, limit of detection and the time to produce one successful run.

| Name of Test | Developer | Nature of Specimen | Target Gene | Sensitivity (PPA) | Specificity (NPA) | Limit of Detection (LoD) | Time to Result | Status | References |
|--------------|-----------|--------------------|-------------|------------------|------------------|------------------------|----------------|--------|------------|
| Non-Isothermal: RT-PCR | Xpert ® Xpress SARS-CoV-2/Flu/RSV | Cepheid | NS, NPS, OPS, MTS, NA, NW | E, N2 | 97.9% | 100% | 131 GCE/mL | 45 min run | EUA | [33–35] |
| | Cobas ® SARS-CoV-2 & Influenza A/B: cobas Liat System | Roche Molecular Systems | NPS, NS | Orf1ab, N | 100% | 97.4% | 0.012 TCID<sub>50</sub>/mL | 20 min run | EUA | [36,37] |
| | Cobas ® SARS-CoV-2 Test | Roche Molecular Systems | NS, NPS, OPS | Orf1ab, E | 100% | 95.5% | 0.007 TCID<sub>50</sub>/mL | 3.5 h run | EUA; CE-IVD | [33,38–40] |
| | Accula ™ SARS-CoV-2 Test | Mesa Biotech | NS, MTS | N | 95.8% | 100% | 150 copies/mL | 30 min run | EUA | [41] |
| | BioFire ® Respiratory Panel 2.1-EZ | BioFire Diagnostics | NPS | S, M | 98% | 100% | 6000 copies/mL | 45 min run | EUA | [42] |
| | TaqPath ™ COVID-19 Pooling Kit | ThermoFisher Scientific, Inc. | NPS, NA, BAL | Orf1ab, S, N | 100% | 100% | 10 GCE/reaction | 4 h run | EUA; CE-IVD | [43–45] |
| | Abbott RealTime ™ SARS-CoV-2 | Abbott Molecular | NS, NPS, OPS, BAL | RdRp, N | 100% | 100% | 100 copies/mL | 6.8 h run | EUA | [34,46] |
| Non-Isothermal: RT-qSTAR amplification | PerkinElmer ® SARS-CoV-2 RT-qPCR Reagent Kit | Perkin Elmer Genomics | NPS, OPS, NA | Orf1ab, N | 100% | 100% | 120 copies/mL | 1 h run | CE-IVD, WHO-EUL | [47] |
| | LumiraDx ™ SARS-CoV-2 RNA STAR complete | LumiraDx UK, Ltd. | NPS, OPS, NA, MTS | Orf1ab | 95% | 100% | 1875 copies/mL | 20 min run | EUA | [48] |
| Isothermal: Transcription mediated amplification | Aptima ® SARS-CoV-2 Assay | Hologic, Inc. | NPS, OPS, NS, NA | Orf1ab | 100% | 99.7% | 0.026 TCID<sub>50</sub>/mL | 2.5 h run | EUA; CE-IVD | [49] |
| ISOTHERMAL: RT-LAMP/NEAR | Cue ™ COVID-19 Test for Home and OTC Use | Cue Health, Inc. | NS | N | 97.4% | 99.1% | 2700 copies/mL | 20 min run | EUA | [50] |
| | AQ-TOP ™ COVID-19 Rapid Detection Test PLUS | Seasun Biomaternal, Inc. | NPS, OPS, NS, NA, MTS | Orf1ab, N | 100% | 100% | 1 copy/µL | 2 h run | EUA | [50] |
| | Pro-AmpRT SARS-CoV-2 Test | Pro-Lab Diagnostics | NPS, OPS, NS, NW, MTS | Orf1ab | 96.6% | 100% | 125 copies/swab | 30 min run | EUA | [52] |
| | ID Now ™ COVID-19 (NEAR) | Abbott Diagnostics | NPS, OPS, NS | RdRp | 100% | 100% | 125 GCE/mL | 13 min run | EUA; CE-IVD | [53–55] |
| Isothermal: RT-PCR/CRISPR | Sherlock ™ CRISPR SARS-CoV-2 Kit | Sherlock Biosciences Inc. | NPS, OPS, NS, NPW, NA, BAL | Orf1ab, N | 100% | 100% | 6750 copies/mL | 1 h run | EUA | [56,57] |
| | SARS-CoV-2 DETECTR ™ Reagent Kit | Mammoth Biosciences, Inc. | NPS, OPS, MTS, NPA, NA | N | 95% | 100% | 20,000 copies/mL | 15 min run | EUA | [58] |
| | Caspr Lyo-CRISPR SARS-CoV-2 Kit (FAM) | Caspr Biotech | NS, NPS, OPS | Orf1ab, N | 99% | 99% | 25,000 copies/mL | 1 h run | EUA | [59] |

Abbreviations: PPA, Positive Percentage Agreement; NPA, Negative Percentage Agreement; RT-PCR, Reverse Transcriptase-Polymerase Chain Reaction; RT-qSTAR, Reverse Transcriptase-Selective Temperature Amplification Reaction; RT-LAMP, Reverse Transcriptase-Loop Mediated Isothermal Amplification; NEAR, Nicking Enzyme Amplification Reaction; CRISPR, Clustered Regularly Interspersed Small Palindromic Repeats; NPS, Nasopharyngeal Swab; OPS, Oropharyngeal Swab; NS, Nasal Swab; NPA, Nasopharyngeal Aspirates; NA, Nasal Aspirates; NW, Nasal Wash; MTS, Mid-turbinate Nasal Swab; BAL, Bronchiolar Lavage; E, Envelope Protein; N, Nucleocapsid Protein; S, Spike Protein; M, Membrane Protein; TCID<sub>50</sub>, tissue culture infectious dose infecting 50% of cells; GCE, Genomic copy equivalents; EUA, Emergency Use Authorization.
Assay selection relies on several factors, including availability of reagents, cost, throughput and performance characteristics [32]. Various publications have appeared over the past year, comparing the performance characteristics of the different commercial assays. One publication from Moran et al. tested 103 specimens on the Roche cobas SARS-CoV-2 test and Cepheid Xpert Xpress SARS-CoV-2 assay and found that 42 tested positive and 60 tested negative with both systems for agreement of 99% [60]. Rhoads et al. tested 96 samples using the CDC EUA as the gold standard and found the positive predictive value of the Diasorin Simplexa COVID-19 Direct assay to be 96% with four false negative samples [33]. A multicenter study of the Cepheid Xpert Xpress SARS-CoV-2 test, a rapid PCR instrument widely available in many clinical labs, demonstrated an LOD of 0.01 PFU/mL. When residual clinical samples were compared to various other PCR assays, it demonstrated a 99.5% positive agreement and 95.8% negative agreement [33]. Fung et al. compared the analytic limit of detection across seven molecular platforms using a pool of positive patient samples quantified via digital droplet PCR. Limits of detection ranged from <10 to 74 copies/mL for commercial high-throughput laboratory analyzers (Roche cobas SARS-CoV-2 Test, Abbott RealTime SARS-C0V-2 assay and Hologic Panther Fusion SARS-CoV-2 assay) and 167 to 511 copies/mL for sample-to-answer (DiaSorin Simplexa COVID-19 Direct assay, GenMark ePlex SARS-CoV-2 Test) and point-of-care instruments (Abbott ID NOW COVID-19 test) [34]. Overall, most commercial RT-PCR assays show excellent analytic sensitivity [38,61–68]. Differences in results may be due to a number of factors, including whether there is a full extraction step prior to amplification [69], whether the patient has a low viral load close to the limit of detection of the assay [69], volume of sample tested and assay design, such as targets chosen [32]. Finally, the quality of the sample received likely has a significant impact on the likelihood of a reliable result [32,70].

One potential advantage of RT-PCR-based tests is the ability to generate a cycle threshold (Ct) value. Ct values have been suggested as a surrogate for viral load [71,72]. The Ct value refers to the number of PCR cycles needed to amplify the target sequence to a detectable level [26]. A specimen containing more virus (higher viral load) will need fewer PCR cycles to produce a positive signal; thus, a lower Ct value implies a higher viral load in the original sample. In assays with more than one target, more than one Ct value may be generated. However, caution must be used in the interpretation of Ct values generated by assays intended to produce a qualitative result (e.g., detected or positive vs. not detected or negative) and that have not been designed to produce quantitative results or and have not been standardized against control samples of a known concentration. In some NAAT assays, the relationship between the Ct value and the concentration of target RNA in the sample may not be linear [72]. Another caveat is that a Ct value generated in one assay platform cannot be correlated directly with a value generated using a different assay due to heterogeneity among the targets and amplification protocols used by different assays and test platforms. Additionally, variability in collection techniques as well as the intrinsic heterogeneity of specimens that contain respiratory secretions contribute to the difficulty of standardizing the viral loads in these samples [72]. Further complicating interpretation of their significance is the finding that Ct values overlap in specimens from symptomatic and asymptomatic patients [73,74] and may not always indicate disease severity.

Disadvantages of PCR testing include the need for specialized and costly reagents, expensive laboratory instrumentation, and highly skilled laboratory personnel. Processing large numbers of specimens is time-consuming and even with automation of many processing steps can take a prolonged period of time to generate results [75,76]. One major limitation of RT-PCR methods is that the tests are overly sensitive and do not distinguish between active infection and non-viable virus [76]. It has been demonstrated that in individuals with COVID-19, viral shedding approximately begins 2–3 days before symptoms appear [77]. The average duration of viral shedding is 20 days [78]; however, viral shedding by immunocompromised hosts may be prolonged for 3–5 months or more [79,80]. In some cases, the shed virus may still be viable. Shedding of replication-competent SARS-CoV-2...
has been shown in cell cultures inoculated with respiratory samples from two patients with prolonged, severe COVID-19 [81].

Transcription-mediated amplification is an alternate type of NAAT testing that forms the basis for the APTIMA assay performed on the high-throughput Panther platform. After hybridizing the viral RNA to a T7 promoter primer, it is reverse-transcribed into a complementary cDNA. The target RNA strand is subsequently degraded by RNase H, leaving a single-stranded cDNA that includes the T7 promoter. An additional primer is used to generate a double-stranded DNA. T7 RNA polymerase then transcribes the ds-DNA into RNA amplicons, which can then restart the process, allowing this exponential amplification [82]. Its performance characteristics suggest the assay is highly sensitive [83].

Other NAAT methods that have been considered for SARS-CoV-2 test manufacturing include reverse transcriptase loop-mediated isothermal amplification (RT-LAMP), nicking endonuclease amplification reaction (NEAR), and Recombinase Polymerase Amplification (RPA) [84]. The increasing need for efficient and rapid testing has also opened the door to alternate approaches such as the quantitative Selective Temperature Amplification Reaction (qSTAR) technology, a qualitative non-isothermal nucleic acid amplification technique based on a two-step cycling protocol that capitalizes on the activity of polymerase and a nicking enzyme and shuttling between temperatures [85]. For RNA STAR, complete incorporation of an extraction buffer allows the sample to be loaded directly, removing the extraction step and significantly shortening the hands-on time by combining lysis and amplification into a single step [85].

Finally, there has been much interest in use of innovative technologies such as clustered regularly interspaced short palindromic repeats (CRISPR) [48], Specific High Sensitivity Enzymatic Reporter UnLocking (SHERLOCK) [56] and MassARRAY [86]. The MassARRAY (Agena Bioscience) is a novel multiplex reverse transcription RT-PCR/MALDI-TOF-based system with a scalable high-throughput capacity and an increased sensitivity achieved by coupling of RT-PCR and mass spectrometry along with a multitarget (N1, N2, N3, ORF1ab, orf1) interrogation of the viral genome. However, a possible limitation to the use of platform as an end-point detection method is that it relies on end-product quantification, and thus does not generate Ct values. To date, the MassARRAY has obtained an FDA EUA for SARS-CoV-2 detection in upper respiratory (nasopharyngeal swab, oropharyngeal swab, nasal and mid-turbinate swabs, and nasal and nasopharyngeal aspirate) and lower respiratory (bronchoalveolar lavage) specimens collected and stored in VTM or UTM [87].

SARS-CoV-2 genetic variability has become a pressing issue, particularly in the context of the worldwide emergence of variants of concern and the potential to affect diagnostic performance. Of note, early in the pandemic, Artesi et al. reported on a recurrent mutation at position 26,340 of SARS-CoV-2 associated with dropout of the E gene on the Roche cobas SARS-CoV-2 Test [88]. More recently, Bal et al. reported a spike deletion H69-V70 identified in several variants, leading to S gene target dropout in the TaqPath qPCR (Thermo Fisher, Waltham, MA, USA) assay [43]. A recent study by Wang et al. using a nucleotide- and gene-based analysis determined that of all currently targeted genes, the N gene is the most prone to mutations, followed by the E gene, as opposed to ORF1ab, which showed a higher diagnostic reliability [89].

Even though the impact of variants on test performance is currently predicted to be low, laboratories should monitor routinely for target failure. This also highlights the importance of incorporating redundancy by targeting more than one target of the viral genome in order to decrease the likelihood of false negative results.

The need for rapid, accurate diagnosis to facilitate appropriate implementation of respiratory isolation measures and patient management has led to the development of point of care testing (POCT); however, there have been concerns with the performance of these tests in some clinical settings. There are currently six rapid point-of-care (POC) NAATs that have received emergency use authorization (EUA) by US Food and Drug Administration (FDA) for point of care use to detect SARS-CoV-2: the Cue COVID-19 test, Abbott ID NOW, Cepheid Xpert Xpress SARS-CoV-2 test, Roche Cobas SARS-CoV-2 & Influenza A/B on the Cobas Liat System, Mesa BioTech Accula SARS-CoV-2 and BioFire Respiratory Panel 2.1-EZ.
Hansen et al. compared results from 357 nasopharyngeal swabs tested on the cobas SARS-CoV-2 & Influenza A/B Assay run on the Laboratory in a tube (LIAT) instrument to the Roche cobas SARS-CoV-2 Test. The overall agreement was found to be 98.6% (352/357); the positive percent agreement for SARS-CoV-2 was 100% (162/162) and the negative percent agreement was 97.4% (190/195) [36]. Although overall this study demonstrated excellent performance characteristics, the FDA recently issued a warning concerning the risks for false positives [90]. Another common POCT test, the Abbott ID now COVID 19 test, was compared to the Cepheid Xpert Xpress SARS-CoV-2 assay using dry nasal swabs. Overall, results from testing by the ID Now agreed for 17 of 31 positive Xpert Xpress samples, with a positive percent agreement of 54.8%. The ID Now results matched 69 of the 70 negative Xpert Xpress results, with 1 positive detected by ID Now but not by Xpert Xpress, for a negative percent agreement of 98.6% [91]. Multiple studies have found lower positive agreement for the ID NOW in comparison to more sensitive molecular platforms [54,60,61,63]. As there is a need for rapid testing results in many settings, particularly emergency rooms, it has been proposed that multistep testing algorithms be developed [92]; however, further research is likely required to formalize this guidance. Another point of care NAAT test is the Cue COVID-19 Test for Home and Over the Counter (OTC) Use. It is an isothermal nucleic acid amplification assay which tests anterior nares samples that are self-collected by adults or collected by an adult from children. One study from the Mayo clinic compared results from the Cue POCT to standard of care testing in a central lab using either the Hologic assay or an LDT [93]. They found excellent positive and negative predictive values; however, of note, in this study, the Cue swabs were collected by nurses and the testing was carried out by MLTs, not patients, as the product is designed for [93].

5.2. Rapid Antigen Tests (RATs)

Rapid antigen tests (RATs), which detect the presence of viral proteins, are another form of POCT (Table 2). Most of these types of tests are lateral-flow immunoassays that create a fluorescent band on the test strip if the target viral proteins are present [6]. These tests are usually cheap and rapid. Beck et al. compared 346 paired NPS tested on both the Sofia Quidel and Hologic Panther Aptima assays and found overall lower agreement amongst the positive samples compared to the negatives (PPA 77% vs. NPA 99.6%). However, it is notable that the PPA of the SOFIA test with the APTIMA TMA test was 82.0% for patients tested ≤ 5 days from symptom onset and 54.5% for patients tested > 5 days from symptom onset [94]. Young et al. compared the BD Veritor System for Rapid Detection of SARS-CoV-2 to the Lyra SARS-CoV-2 assay and, in a separate analysis, compared the BD Veritor System for Rapid Detection of SARS-CoV2 antigen test to the Sofia SARS Antigen FIA. Compared to the Lyra PCR assay, the positive predictive agreement was 88% for patients with two or more symptoms consistent with COVID-19 but dropped to 57.1% and to 66.7% for specimens from patients with only one symptom. Overall, the two rapid antigen tests were reported to have similar performance characteristics [95]. A Cochrane review of rapid antigen tests found that test sensitivity ranged from 30% to 80% with a pooled sensitivity of 56% [96]. It has been proposed that despite a lower positive predictive value in comparison to NAAT tests, there are potential uses for antigen tests. One use could be for rapid diagnosis of symptomatic patients. However, negative results would not rule out asymptomatic carriage and would likely still require PCR confirmation, and positive findings in asymptomatic require a second methodology to rule out a false positive result. Another potential use for the test might be to predict which patients are likely to be infectious to others. One group demonstrated that antigen positivity has a 90% PPV of having culturable virus vs. only 70% amongst PCR positive patients [97]. The CDC has proposed an algorithm for how to best use antigen testing [98]. Even though many of the commercially available antigen tests target the viral nucleocapsid protein (N gene), the very few assays that target the spike protein (S gene) may be negligibly affected by current emergent variants. However, to date, there are no studies confirming the potential impact of variants in antigen-based test performance [99].
Table 2. Comparative list of rapid antigen tests for the detection of SARS CoV-2, by manufacturer, origin of specimen, target gene, sensitivity, specificity, limit of detection, and the time to produce one successful run.

| Name of Test | Developer | Nature of Specimen | Target Antigen | Sensitivity (PPA) | Specificity (NPA) | Limit of Detection (LoD) | Time to Result | Status | References |
|--------------|-----------|--------------------|----------------|------------------|------------------|-------------------------|----------------|--------|------------|
| Sofia ® SARS Antigen FIA | Quidel Corporation | NPS, NS, ANS | Nucleocapsid Protein | 100% | 100% | 113 TCID$_{50}$/mL | 15 min run | EUA | [94,95,100] |
| BD Veritor ™ System for RAPID Detection of SARS-CoV-2 & Flu A+B | Becton, Dickinson and Company | NS | Nucleocapsid Protein | 84% | 100% | 140 TCID$_{50}$/mL | 15 min run | EUA | [95,101] |
| InteliSwab ™ COVID-19 Rapid Test Pro | OraSure Technologies, Inc. | NS | Nucleocapsid Protein | 84% | 98% | 2500 TCID$_{50}$/mL | 35 min run | EUA: CE-IVD | [102] |
| SCoV-2 Ag Detect ™ Rapid Test | InBios International, Inc. | ANS, NS | Nucleocapsid Protein | 86.6% | 100% | 6300 TCID$_{50}$/mL | 25 min run | EUA: CE-IVD | [103] |
| Celltrion DiaTrust ™ COVID-19 Ag Rapid Test | Celltrion USA, Inc. | NPS | Nucleocapsid Protein, Spike RBD | 93.3% | 99% | 32 TCID$_{50}$/mL | 15 min run | EUA | [104] |
| BinaxNOW ™ COVID-19 Ag Card2 Home Tool | Abbott Diagnostics Scarborough, Inc. | NS | Nucleocapsid Protein | 84.6% | 98.5% | 140.6 TCID$_{50}$/mL | 15 min run | EUA | [105] |
| Status ™ COVID-19 Antigen Test | Princeton BioMeditech Corporation. | NPS | Nucleocapsid Protein | 93.9% | 100% | 2700 TCID$_{50}$/mL | 15 min run | EUA | [106] |

Abbreviations: PPA, Positive Percentage Agreement; NPA, Negative Percentage Agreement; NPS, Nasopharyngeal Swab; OPS, Oropharyngeal Swab; ANS, Anterior Nasal Aspirates; NS, Nasal Swab; NPA, Nasopharyngeal Aspirates; NA, Nasal Aspirates; NW, Nasal Wash; MTS, Mid-turbinate Nasal Swab; BAL, Bronchiolar Lavage; TCID$_{50}$, tissue culture infectious dose infecting 50% of cells; GCE, Genomic copy equivalents; EUA, Emergency Use Authorization.
5.3. SARS CoV-2 Antibody Tests

Serologic testing is an important tool at the population level, since establishing seroprevalence can enhance understanding of the epidemiology of COVID-19 and assist in public health planning. For an individual, serology can help establish potential susceptibility to infection or may be used as an adjunct to PCR testing for diagnosis, particularly when patients present late in the course of illness when the virus may no longer be detectable [107]. For symptomatic individuals, IgM can be detected at a median of 5 days, and IgG at a median of 14 days, after symptom onset [108]. IgG antibodies have been shown to correlate with disease severity, decline at varying rates, and may be detectable for months following infection [109,110]. However, between 4% and 10% of the individuals with confirmed SARS-CoV-2 infection may have an undetectable or delayed antibody response [111]. The humoral response includes antibodies directed against RBD, S and N proteins, which serve as the primary targets for COVID-19 serologic assays [6]. Some general limitations of serology studies for COVID-19 include: it is unknown how long protection lasts; protection is unlikely to be durable given short-lived immunity to other coronaviruses; some people with mild/asymptomatic infections never develop antibody responses at all; serology cannot be used in acute diagnosis; combination IgM/IgG assays are of questionable value due to concerns of cross-reactivity of IgM and other coronavirus antibodies [6,82,107,112,113].

At present, serology is not recommended to assess the response to COVID-19 vaccination. Since vaccines induce antibodies to specific viral protein targets, post-vaccination serologic test results will be negative in persons if the test used does not detect antibodies induced by the vaccine [113]. As for direct viral testing, there is no gold standard for antibody testing. RT-PCR positivity is currently used as a surrogate; however, patients may have negative serologic results with a positive PCR test for any number of reasons including: (1) failure to mount a measurable serologic response in immunocompromised hosts; (2) clearance of infection by T cells or other immune mechanisms; (3) presence of an interfering substance in the patient’s serum; (4) false positive PCR result in a patient who did not have an infection with SARS-CoV-2 [114].

Serologic testing assays can be broadly divided into three main categories: detection of total antibodies, detection of specific antibody subclasses (IgG, IgM or IgA), and detection of neutralizing antibodies (nAbs) using qualitative or semi-quantitative methods [107]. Detection of IgA is not routinely recommended for clinical assays [113]; detection of total antibodies may enhance sensitivity [114]. Currently, commercially produced antibody methods include rapid diagnostic tests (RDTs), enzyme-linked immunosorbent assays (ELISA) and chemiluminescence immunoassays (CLIA) [107]. RDTs are based on antibody detection using a nitrocellulose membrane. The sample is loaded onto a loading pad and then flows via capillary motion when buffer is added. Antibodies in the specimen bind to nanoparticles on the membrane which then are captured by anti-human antibodies. The convenience of these assays makes them popular as POCTs but there has been a wide variability in performance characteristics for these assays across different vendors. For ELISA-based methods, patient specimens are added to a tube or well of a multiassay plate coated with viral antigens. A secondary (anti-human) antibody is linked to an enzyme that will produce a color readout when its substrate is added. Development of color when the substrate is added indicates that a human antibody to the viral antigen bound to the well or tube was present in the patient specimen. Multiwell plate assays or high-throughput platforms allow for large-scale testing but are expensive and must be performed in a laboratory. CLIA is a similar technique to ELISA, but a fluorescent molecule is used as the indicator [107].

Several available serologic assays were compared directly by the National SARS-CoV-2 serology assay evaluation group, including four commercial and one home-brew serologic assay: the SARS-CoV-2 IgG assay (Abbott), Liaison SARS-CoV-2 S1/S2 IgG assay (Diasorin), Elecsys Anti-SARS-CoV-2 assay (Roche), SARS-CoV-2 total assay (Siemens) and the Oxford Immunoassay. The results for 976 pre-pandemic blood samples and 536 samples from
patients with confirmed SARS-CoV-2 infection, collected > 20 days after symptom onset, were evaluated. All five assays demonstrated a sensitivity and specificity of >90%, with a sensitivity of >98% for specimens obtained > 30 days after symptom onset [114]. Similar findings have been obtained in other comparative studies [115–118]. There are currently over fifty serologic assays with FDA EUA [32]. As a result, comparison of performance can be difficult due to differences in the approach, the sample size, sample collection time and disease prevalence in the population tested by each manufacturer, which vary widely [107]. A summary of some of the currently available serologic tests can be found in Table 3.

### Table 3. Comparative list of serology tests for the detection of SARS-CoV-2 by manufacturer, origin of specimen, target antibody, sensitivity, specificity and the time to produce one successful run.

| Serology Tests                                      | Developer                     | Nature of Specimen | Target Antibody | Sensitivity (PPA) | Specificity (NPA) | Time to Result | Status          | References        |
|-----------------------------------------------------|-------------------------------|--------------------|-----------------|-------------------|-------------------|----------------|-----------------|------------------|
| Rapid Serology Test (RST)                           |                               | WB, EDTA P, LHP, S| IgM, IgG        | IgM (100%); IgG (96.7%) | IgM (98.9%); IgG (97.5%) | ~22 min run | EUA; CE-IVD     | [119]            |
| Siemens Clarity COVIBLOCK ™ COVID-19 IgM/IgG Rapid Test Cassette | Clarity Diagnostics, LLC. | WB, EDTA P, SCP, LHP, S | IgM, IgG | IgM (90%); IgG (93.3%) | IgM (100%); IgG (98.9%) | 10 min run | EUA; CE-IVD     | [120]            |
| Helagene™ COVID-19 IgG/IgM Rapid Test Cassette     | Helagen Scientific, LLC.      | WB, EDTA P, LHP, SCP, S | IgM, IgG | IgM (97.9%); IgG (97.2%) | IgM & IgG (100%) | 10 min run | EUA              | [121]            |
| SCITE-flux ™ COVID-19 IgG Test                     | Suntech, Inc.                  | WB, EDTA P, LHP, SCP, S | IgG          | IgG (93.3%)         | IgG (100%) | 10 min run | EUA; CE-IVD     | [122]            |
| ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)           |                               |                    |                |                   |                   |               |                 |                  |
| COVID-19 Antibody Combo Detection Kit              | Symbiotica, Inc.              | DBS               | IgG            | IgG (100%); IgG (98%) | N/A              |               | EUA; CE-IVD     | [123]            |
| COVID-SeroKlir ™, Kantaro semi-quantitative SARS-CoV-2 IgG Antibody Kit | Kantaro Biosciences, LLC. | LHP, S            | IgG            | IgG (99.6%) | N/A              |               | EUA; CE-IVD     | [124]            |
| cPASS ™ SARS-CoV-2 Neutralization Antibody Detection Kit | Gartscript USA, Inc.         | EDTA P            | IgG            | IgG (100%) | N/A              |               | EUA; CE-IVD     | [125]            |
| ZEUS/ELISA ™ SARS-CoV-2 IgG Test System            | ZEUS Scientific, Inc.         | EDTA P, LHP, SCP, S | IgG            | 93.3%             | 100%              | 30 min run | EUA              | [126]            |
| COVID-19 ELISA IgG Antibody Test                   | Mount Sinai Laboratories      | EDTA P            | IgG            | 92.0%             | 100%              | N/A          | EUA; CE-IVD     | [127]            |
| CHEMOLUMINESCENT IMMUNOASSAY (CLIA)                 |                               |                    |                |                   |                   |               |                 |                  |
| Dimension EXL SARS-CoV-2 IgG Test                  | Siemens Healthcare Diagnostics, Inc. | EDTA P, LHP, S | IgG            | 92%               | 99.9%             | 25 min run | EUA              | [128]            |
| VITROS ™ Immunoassays Products Anti-SARS-CoV-2 IgG Total Reagent Pack | Ortho-Clinical Diagnostics | EDTA P            | IgG            | 100%             | 100%              | 48 min run | EUA; CE-IVD     | [129]            |
| Elecsys ™ Anti-SARS-CoV-2 IgG Assay Kit            | Roche Molecular Systems       | EDTA P, LHP, S    | IgG            | 88.1%             | 99.81%            | 10 min run | EUA; CE-IVD     | [130]            |
| AccuChek ™ SARS-CoV-2 IgM Test                     | Beckman Coulter               | EDTA P, LHP, SCP, S | IgM          | 95.3%            | IgG (100%) | 30 min run | EUA; CE-IVD     | [131]            |
| Liaison ™ SARS-CoV-2/3 IgG Test                    | DiaScreen, Inc.               | EDTA P, LHP, S    | IgG            | 93.2%             | 99.8%             | 30 min run | EUA; CE-IVD     | [132]            |
| BioCheck SARS-CoV-2 IgG Antibody Test Kit          | Biocheck, Inc.                | S                 | IgG            | 100%             | 100%              | 30 min run | EUA              | [133]            |

Abbreviations: PPA, Positive Percentage Agreement; NPA, Negative Percentage Agreement; WB, Whole Blood; P, Plasma (EDTA, Lithium Heparin, Sodium Citrate, Sodium Heparin); S, Serum; DBS, Dried Blood Smear; EUA, Emergency Use Authorization.

The diversity of molecular assays targeting different SARS-CoV-2 genes has enhanced diagnosis capacity and precise identification of SARS-CoV-2 infections. However, the accumulation of nucleotide changes during viral replication has led to the emergence of variant viruses and potentially impacts diagnostic test accuracy for detection of SARS-CoV-2 infection. This highlights the importance of monitoring performance of already released and under-development assays, as well as the need for continued genomic surveillance aimed at detection of variants and their impact on diagnostic target regions. Additionally, the wide circulation of virus variants and concerns regarding the ability of current molecular assays to reliably identify future SARS-CoV-2 emerging variants emphasizes the pressing need for increased and timely whole genome sequencing and surveillance.

6. Conclusions

In one year, we have learnt a great deal about SARS-CoV-2, a novel coronavirus. As the pandemic continues, the state of knowledge will continue to evolve. This review provides an overview to assist providers in better understanding the testing options for detection of SARS-CoV-2 infections and to assist in the management of patients with COVID-19.
Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. European Centre for Disease Prevention and Control. Cluster of Pneumonia Cases Caused by a Novel Coronavirus, Wuhan, China; 17 January 2020; ECDC: Stockholm, Sweden, 2020.

2. Astuti, I. Ysrafil Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. *Diabetes Metab. Syndr. Clin. Res. Rev.* 2020, 14, 407–412. [CrossRef] [PubMed]

3. Andersen, K.G.; Rambaut, A.; Lipkin, W.I.; Holmes, E.C.; Garry, R.F. The proximal origin of SARS-CoV-2. *Nat. Med.* 2020, 26, 450–452. [CrossRef]

4. Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.-L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 2020, 367, 1260–1263. [CrossRef] [PubMed]

5. Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. *Science* 2020, 367, 1444–1448. [CrossRef] [PubMed]

6. Ortiz-Prado, E.; Simbana-Rivera, K.; Gomez-Barreno, L.; Rubio-Neira, M.; Guaman, L.P.; Kyriakidis, N.C.; Muslin, C.; Jaramillo, A.M.G.; Barba-Ostria, C.; Cevallos-Robalino, D.; et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. *Diagn. Microbiol. Infect. Dis.* 2020, 98, 115094. [CrossRef] [PubMed]

7. Gralinski, L.E.; Menachery, V.D. Return of the Coronavirus: 2019-nCoV. *Viruses* 2020, 12, 135. [CrossRef]

8. Safiabadi Tali, S.H.; LeBlanc, J.J.; Sadiq, Z.; Oyewunmi, O.D.; Camargo, C.; Nikpour, B.; Armanfard, N.; Sagan, S.M.; Jahanshahi-Anbuh, S. Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. *Clin. Microbiol. Rev.* 2021, 34, e00228-20. [CrossRef]

9. Hatfield, K.M.; Reddy, S.C.; Forsberg, K.; Korhonen, L.; Garner, K.; Goudot, G.; Hauw-Berlemont, C.; Le, L.; Caudron, E.; Carrabin, S.; et al. Facility-Wide Testing for SARS-CoV-2 in Nursing Homes—Seven U.S. Jurisdictions, March–June 2020. *Morb. Mortal. Wkly. Rep.* 2020, 69, 1095–1099. [CrossRef]

10. Overview of Testing for SARS-CoV-2 (COVID-19). Available online: https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html (accessed on 30 March 2021).

11. Hanson, E.K.; Caliendo, A.M.; Arias, A.C.; Hayden, M.K.; Englund, A.J.; Lee, M.J.; Loeb, M.; Patel, R.; Alayli, E.A.; Altayar, O.; et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. *Clin. Infect. Dis.* 2021. [CrossRef]

12. Sullivan, C.B.; Schwajle, A.T.; Jensen, M.; Li, L.; Dlouhy, B.J.; Greenlee, J.D.; Walsh, J.E. Cerebrospinal Fluid Leak after Nasal Swab Testing for Coronavirus Disease 2019. *JAMA Otolaryngol. Neck Surg.* 2020, 146, 1179. [CrossRef]

13. Péré, H.; Podglajen, I.; Wack, M.; Flamaron, E.; Miraunt, T.; Goudot, G.; Hauw-Berlemont, C.; Le, L.; Caudron, E.; Carrabin, S.; et al. Nasal Swab Sampling for SARS-CoV-2: A Convenient Alternative in Times of Nasopharyngeal Swab Shortage. *J. Clin. Microbiol.* 2020, 58. [CrossRef]

14. To, K.K.-W.; Tsang, O.T.-Y.; Yip, C.C.-Y.; Chan, K.-H.; Wu, T.-C.; Chan, J.M.-C.; Leung, W.-S.; Chik, T.S.-H.; Choi, C.Y.-C.; Kandamby, D.H.; et al. Consistent Detection of 2019 Novel Coronavirus in Saliva. *Clin. Infect. Dis.* 2020, 71, 841–843. [CrossRef] [PubMed]

15. Wyllie, A.L.; Fournier, J.; Casanovas-Massana, A.; Campbell, M.; Tokuyama, M.; Vijayakumar, P.; Warren, J.L.; Geng, B.; Muenker, M.C.; Moore, A.J.; et al. Saliva or Nasopharyngeal swab specimens for detection of SARS-CoV-2. *N. Engl. J. Med.* 2020, 383, 1283–1286. [CrossRef]

16. Jamal, A.J.; Mohammad, M.; Coomes, E.; Powis, J.; Li, A.; Paterson, A.; Anceva-Sami, S.; Barati, S.; Crowl, G.; Faheem, A.; et al. Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin. Infect. Dis.* 2020, ciaa848. [CrossRef]

17. Huang, N.; Pérez, P.; Kato, T.; Mikami, Y.; Okuda, K.; Gilmore, R.C.; Conde, C.D.; Gasmi, B.; Stein, S.; Beach, M.; et al. SARS-CoV-2 infection of the oral cavity and saliva. *Nat. Med.* 2021, 27, 892–903. [CrossRef] [PubMed]

18. Savela, E.S.; Winnett, A.; Romano, A.E.; Porter, M.K.; Shelby, N.; Akana, R.; Ji, J.; Cooper, M.M.; Schlenker, N.W.; Reyes, J.A.; et al. SARS-CoV-2 is detectable using sensitive RNA saliva testing days before viral load reaches detection range of low-sensitivity nasal swab tests. *medRxiv* 2021. [CrossRef]

19. Winichakoon, P.; Chaiwarith, R.; Liwsrisakun, C.; Salee, P.; Goonna, A.; Limsukon, A.; Kaewpoowat, Q. Negative Nasopharyngeal and Oropharyngeal Swabs Do Not Rule Out COVID-19. *J. Clin. Microbiol.* 2020, 58. [CrossRef]

20. Menter, T.; Haslbauer, J.D.; Nienhold, R.; Savic, S.; Hopfer, H.; Deigendesch, N.; Frank, S.; Turek, D.; Willi, N.; Pargger, H.; et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. *Histopathology* 2020, 77, 198–209. [CrossRef]

21. Bosch, B.J.; Smits, S.L.; Haagmans, B.L. Membrane ectopeptidases targeted by human coronaviruses. *Curr. Opin. Virol.* 2014, 6, 55–60. [CrossRef] [PubMed]

22. Mohammadi, A.; Esmaeizadeh, E.; Li, Y.; Bosch, R.J.; Li, J.Z. SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis. *EBioMedicine* 2020, 59, 102903. [CrossRef]
23. Hou, Y.; Okuda, K.; Edwards, C.E.; Martinez, D.R.; Asakura, T.; Dinnon, K.H.; Kato, T.; Lee, R.E.; Yount, B.L.; Mascenik, T.M.; et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. *Cell* **2020**, *182*, 429–446. [CrossRef]

24. Radbel, J.; Jagpal, S.; Roy, J.; Brooks, A.; Tischfeld, J.; Sheldon, M.; Bixby, C.; Witt, D.; Gennaro, M.L.; Horton, D.B.; et al. Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Is Comparable in Clinical Samples Preserved in Saline or Viral Transport Medium. *J. Mol. Diagn.* **2020**, *22*, 871–875. [CrossRef]

25. Rodino, K.; Espy, M.J.; Buckwalter, S.P.; Walchak, R.C.; Germer, J.J.; Ferholz, E.; Boerger, A.; Schuetz, A.N.; Yao, J.D.; Binninger, M.; Evaluation of Saline, Phosphate-Buffered Saline, and Minimum Essential Medium as Potential Alternatives to Viral Transport Media for SARS-CoV-2 Testing. *J. Clin. Microbiol.* **2020**, *58*, 58. [CrossRef]

26. Bustin, S.A.; Nolan, T. RT-qPCR Testing of SARS-CoV-2: A Primer. *Int. J. Mol. Sci.* **2020**, *21*, 3004. [CrossRef]

27. Kilic, T.; Weissleider, R.; Lee, H. Molecular and Immunological Diagnostic Tests of COVID-19: Current Status and Challenges. *iScience* **2020**, *23*, 101406. [CrossRef]

28. Real-Time RT-PCR Assays for the Detection of SARS-CoV-2. Available online: https://www.who.int/docs/default-source/coronaviruse/whoindhouseassays.pdf (accessed on 21 June 2021).

29. Vogels, C.B.F.; Brito, A.F.; Fauver, J.R.; Ott, I.M.; Kalinich, C.C.; Petrone, M.E.; Casanovas-Massana, A.; Muenker, M.C.; Moore, A.J.; et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer–probe sets. *Nat. Microbiol.* **2020**, *5*, 1295–1305. [CrossRef]

30. Corman, V.M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D.K.; Bleicker, T.; Brünink, S.; Schneider, J.; Schmidt, M.L.; et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance* **2020**, *25*, 2000045. [CrossRef] [PubMed]

31. Food and Drug Administration Coronavirus Disease 2019 (COVID-19) EUA Information. Available online: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas (accessed on 30 March 2021).

32. Loeffelholz, M.J.; Tang, Y.-W. Laboratory diagnosis of emerging human coronavirus infections—The state of the art. *Emerg. Microbes Infect.* **2020**, *9*, 747–756. [CrossRef] [PubMed]

33. Loeffelholz, M.J.; Alland, D.; Butler-Wu, S.M.; Pandey, U.; Perno, C.F.; Nava, A.; Carroll, K.C.; Mostafa, H.; Davies, E.; McEwan, A.; et al. Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test. *J. Clin. Microbiol.* **2020**, *58*. [CrossRef]

34. Fung, B.; Gopez, A.; Serravilla, V.; Arevalo, S.; Ho, C.; Deucher, A.; Thornborrow, E.; Chiu, C.; Miller, S. Direct Comparison of SARS-CoV-2 Analytical Limits of Detection across Seven Molecular Assays. *J. Clin. Microbiol.* **2020**, *58*. [CrossRef] [PubMed]

35. Corman, V.M.; Alland, D.; Butler-Wu, S.M.; Pandey, U.; Perno, C.F.; Nava, A.; Carroll, K.C.; Mostafa, H.; Davies, E.; McEwan, A.; et al. Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test. *J. Clin. Microbiol.* **2020**, *58*. [CrossRef]

36. Hansen, G.; Marino, J.; Wang, Z.-X.; Beavis, K.G.; Rodrigo, J.; Labog, K.; Westblade, L.F.; Jin, R.; Love, N.; Ding, K.; et al. Clinical performance of the point-of-care tech with detection of SARS-CoV-2 in 20 minutes: A multicenter study. *J. Clin. Microbiol.* **2020**, *58*. [CrossRef]

37. Roche Molecular Systems. *cobas® SARS-CoV-2 & Influenza A/B Nucleic Acid Test for Use on the cobas Liat System: Instructions for Use; Roche Molecular Systems: South Branchburg, NJ, USA, 2020. Available online: https://www.fda.gov/media/142193/download (accessed on 21 June 2021).

38. Craney, A.R.; Velu, P.D.; Satlin, M.J.; Fauntleroy, K.; Callan, K.; Robertson, A.; La Spina, M.; Lei, B.; Chen, A.; Alston, T.; et al. Comparison of Two High-Throughput Reverse Transcription-PCR Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *J. Clin. Microbiol.* **2020**, *58*. [CrossRef]

39. Roche Molecular Systems. *cobas® SARS-CoV-2 Qualitative Assay for Use on the cobas® 6800/8800 Systems; Roche Molecular Systems: South Branchburg, NJ, USA, 2021. Available online: https://www.fda.gov/media/136049/download (accessed on 21 June 2021).

40. Roche Molecular Systems. *cobas SARS-CoV-2 Test: Instructions for Use; Roche Molecular Systems: South Branchburg, NJ, USA, 2021. Available online: https://www.fda.gov/media/136049/download (accessed on 30 June 2021).

41. Mesa Biotech. *Accula SARS-CoV-2 Test: Instructions for Use; Mesa Biotech: San Diego, CA, USA, 2021. Available online: https://www.mesabiotech.com/wp-content/uploads/2021/02/LBL-60061-Accula-SARS-CoV-2-IFU-03FEB2021.pdf (accessed on 1 July 2021).

42. BioFire Diagnostics. *BioFire Respiratory Panel 2.1-E.Z. (RP2.1-E.Z.): Instructions for Use; BioFire Diagnostics: Salt Lake City, UT, USA, 2020. Available online: https://docs.biofiredx.com/wp-content/uploads/BFR0001-0044-BioFire-RP2.1-EZ-Instructions-for-Use-EUA-1.pdf (accessed on 21 June 2021).

43. Bal, A.; Destras, G.; Gaymard, A.; Stefic, K.; Marlet, J.; Eyrmieux, S.; Regue, H.; Semanas, Q.; D’Aubarede, C.; Billaud, G.; et al. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69–V70, France, August to December 2020. *Eurosurveillance* **2021**, *26*, 2100008. [CrossRef]

44. Thermo Fisher Scientific, Inc. *TaqPath COVID-19 Combo Kit and TaqPath COVID-19 Combo Kit Advanced Instructions for Use; Thermo Fisher Scientific, Inc.: Waltham, MA, USA, 2021. Available online: https://www.fda.gov/media/136112/download (accessed on 21 June 2021).

45. Yu, C.Y.; Chan, K.G.; Yeon, C.Y.; Ang, G.Y. Nucleic Acid-Based Diagnostic Tests for the Detection SARS-CoV-2: An Update. *Diagnostics* **2021**, *11*, 53. [CrossRef]

46. Abbott Diagnostics. *Abbott RealTime SARS-CoV-2: Instructions for Use; Abbott Molecular, Inc.: Des Plaines, IL, USA, 2020. Available online: https://www.fda.gov/media/136258/download (accessed on 1 July 2021).
73. Lee, S.; Kim, T.; Lee, E.; Lee, C.; Kim, H.; Rhee, H.; Park, S.Y.; Son, H.-J.; Yu, S.; Park, J.W.; et al. Clinical Course and Molecular Viral Shedding among Asymptomatic and Symptomatic Patients with SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea. JAMA Intern. Med. 2020, 180. [CrossRef]

74. Lavezzo, E.; Franchin, E.; Ciavarella, C.; Cuomo-Dannenburg, G.; Barzon, L.; Del Vecchio, C.; Rossi, L.; Manganelli, R.; Loregian, A.; Navarin, N.; et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’ J. Nature 2020, 584, 425–429. [CrossRef]

75. Habibzadeh, P.; Mofatteh, M.; Silawi, M.; Ghavami, S.; Faghihi, M.A. Molecular diagnostic assays for COVID-19: An overview. Crit. Rev. Clin. Lab. Sci. 2021, 1–20. [CrossRef]

76. Antonelli, G.; Stefanì, S.; Pistello, M. SARS-CoV-2 diagnostics: Some reflections on current assays. Diagn. Microbiol. Infect. Dis. 2021, 99, 115237. [CrossRef]

77. He, X.; Lau, E.H.Y.; Wu, P.; Deng, X.; Wang, J.; Hao, X.; Lau, Y.C.; Wong, J.Y.; Guan, Y.; Tan, X.; et al. Temporal dynamics in viral shedding and transmissibility of COVID-19 Nat. Med. 2020, 26, 672–675. [CrossRef]

78. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [CrossRef]

79. Avanzato, V.A.; Matson, M.J.; Seifert, S.N.; Pryce, R.; Williamson, B.N.; Anzick, S.L.; Judson, S.D.; Fischer, E.R.; Martens, C.; et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell 2020, 183, 1901–1912.e9. [CrossRef] [PubMed]

80. Choi, B.; Choudhary, M.C.; Regan, J.; Sparks, J.A.; Padera, R.F.; Qiu, X.; Solomon, I.H.; Kuo, H.-H.; Boucau, J.; Bowman, K.; et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med. 2020, 383, 2291–2293. [CrossRef] [PubMed]

81. Folgueira, M.D.; Luczkowiak, J.; Lasala, F.; Pérez-Rivilla, A.; Delgado, R. Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19. Clin. Microbiol. Infect. 2021, 27, 886–891. [CrossRef]

82. Carter, L.J.; Garner, L.V.; Smoot, J.W.; Li, Y.; Zhou, Q.; Saveson, C.J.; Sasso, J.M.; Gregg, A.C.; Soares, D.J.; Beskid, T.R.; et al. Assay Techniques and Test Development for COVID-19 Diagnosis. ACS Cent. Sci. 2020, 6, 591–605. [CrossRef] [PubMed]

83. Gorzalski, A.J.; Tian, H.; Laverdure, C.; Morzunov, S.; Verma, S.C.; VanHooser, S.; Pandori, M.W. High-Throughput Transcription-mediated amplification on the Hologic Panther is a highly sensitive method of detection for SARS-CoV-2. J. Clin. Virol. 2020, 129, 104501. [CrossRef] [PubMed]

84. James, A.S.; Alawneh, J.I. COVID-19 Infection Diagnosis: Potential Impact of Isothermal Amplification Technology to Reduce Community Transmission of SARS-CoV-2. Diagnostics 2020, 10, 399. [CrossRef]

85. LumiraDx SARS-CoV-2 RNA STAR Complete Instructions for Use for Emergency Use Authorization (EUA) Only. Available online: https://www.fda.gov/media/143334/download (accessed on 4 April 2021).

86. Wang, R.; Hozumi, Y.; Yin, C.; Wei, G.-W. Mutations on COVID-19 diagnostic targets. Viruses 2020, 12, 849. [CrossRef] [PubMed]

87. Agena Bioscience. MassARRAY®SARS-CoV-2 Panel Instructions for Use Multiplex RT-PCR/MALDI-TOF Test Intended for the Qualitative Detection of Nucleic Acid from SARS-CoV-2; Agena Bioscience: San Diego, CA, USA, 2021. Available online: https://www.fda.gov/media/143334/download (accessed on 4 April 2021).

88. Artési, M.; Bontems, S.; Gobbel, P.; Franckh, M.; Maes, P.; Boreux, R.; Meex, C.; Melin, P.; Hayette, M.-P.; Bours, V.; et al. A Recurrent Mutation at Position 26340 of SARS-CoV-2 Is Associated with Failure of the E Gene Quantitative Reverse Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay. J. Clin. Microbiol. 2020, 58, e01598-20. [CrossRef]

89. Wang, R.; Hozumi, Y.; Yin, C.; Wei, G.-W. Mutations on COVID-19 diagnostic targets. Genomics 2020, 112, 5204–5213. [CrossRef] [PubMed]

90. Potential for False Results with Roche Molecular Systems, Inc cobas SARS-CoV-2 & Influenza Test for use on cobas-sars-cov-2-influenza-test-use-cobas-liat (accessed on 30 March 2021).

91. Basu, A.; Zinger, T.; Inglima, K.; Woo, K.-M.; Atie, O.; Yurasits, L.; See, B.; Aguerro-Rosenfeld, M.E. Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York City Academic Institution. J. Clin. Microbiol. 2020, 58. [CrossRef]

92. Cradic, K.; Lockhart, M.; Ozbolt, P.; Fatica, L.; Landon, L.; Lieber, M.; Yang, D.; Swickard, J.; Wongchaowart, N.; Fuhrman, S.; et al. Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2. Am. J. Clin. Pathol. 2020, 154, 201–207. [CrossRef]

93. Donato, L.J.; Trivedi, V.A.; Stransky, A.M.; Misra, A.; Pritt, B.S.; Binnicker, M.J.; Karon, B.S. Evaluation of the Cue Health point-of-care COVID-19 (SARS-CoV-2 nucleic acid amplification) test at a community drive through collection center. Diagn. Microbiol. Infect. Dis. 2021, 100, 115307. [CrossRef] [PubMed]

94. Beck, E.T.; Paar, W.; Fojut, L.; Serwe, J.; Jahnke, R.R. Comparison of the Quidel Sofia SARS FIA Test to the Hologic Aptima SARS-CoV-2 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients. J. Clin. Microbiol. 2021, 59. [CrossRef] [PubMed]
95. Young, S.; Taylor, S.N.; Cammarata, C.L.; Varnado, K.G.; Roger-Dalbert, C.; Montano, A.; Griego-Fullbright, C.; Burgard, C.;
Fernandez, C.; Eckert, K.; et al. Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to
PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test. J. Clin. Microbiol. 2020, 58. [CrossRef]

96. Dinnes, J.; Deeks, J.J.; Adriano, A.; Berhane, S.; Davenport, C.; Dittrich, S.; Emperador, D.; Takwoingi, Y.; Cunningham, J.; Beese, S.; et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst. Rev. 2020, 2020, CD013705. [CrossRef]

97. Pekosz, A.; Parvu, V.; Li, M.; Andrews, J.C.; Manabe, Y.C.; Kodsi, S.; Gary, D.S.; Roger-Dalbert, C.; Leitch, J.; Cooper, C.K. Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates with Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture. Clin. Infect. Dis. 2021. [CrossRef]

98. Interim Guidance for Antigen Testing for SARS-CoV-2. Available online: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html (accessed on 13 May 2021).

99. Foundation for Innovative New Diagnostics. The Impact of Novel Variants of SARS-CoV2 on Diagnostic Testing. Available online: https://www.fnddx.org/covid-19/novel-variants/ (accessed on 13 May 2021).

100. Quidel Corporation. Sofia SARS Antigen FIA: Instructions for Use; Quidel Corporation: San Diego, CA, USA, 2020; Available online: https://www.medline.com/media/catalog/docs/MKT/WP/COVID19/Quidel-Sofia-SARS-Antigen-FIA-Instructions-for-Use-06-20.pdf (accessed on 1 July 2021).

101. Veritor System for Rapid Detection of SARS-CoV-2. Available online: https://www.fda.gov/media/139755/download (accessed on 21 June 2021).

102. Orasure Technologies, Inc. InteliSwab COVID-19 Rapid Test Pro: Instructions for Use; Orasure Technologies, Inc.: Bethlehem, PA, USA, 2020. Available online: https://www.fda.gov/media/149918/download (accessed on 21 June 2021).

103. InBios International, Inc. SCoV-2 Ag Detect Rapid Test: Instructions for Use; InBios International, Inc.: Seattle, WA, USA, 2020. Available online: https://www.fda.gov/media/148353/download (accessed on 21 June 2021).

104. Celltrion USA, Inc. Celltrion DiaTrust COVID-19 Ag Rapid Test: Instructions for Use; Celltrion USA, Inc.: Jersey City, NJ, USA, 2020. Available online: https://www.fda.gov/media/147694/download (accessed on 21 June 2021).

105. Damaschik, M.; Donicke, T.; Lux, F. Multiclass Text. Classification on Unbalanced, Sparse and Noisy Data; Linköping University Electronic Press: Turku, Finland, 2019; pp. 58–65. Available online: https://www.aclweb.org/anthology/W19-6207 (accessed on 21 June 2021).

106. Princeton BioMeditech, Corp. Status COVID-19/Flu: Instructions for Use; Princeton BioMeditech, Corp: Princeton, NJ, USA, 2020. Available online: https://www.fda.gov/media/145697/download (accessed on 21 June 2021).

107. Zhang, Y.V.; Wiencek, J.; Meng, Q.H.; Theel, E.S.; Babic, N.; Sepiashvili, L.; Pecora, N.D.; Slev, P.; Cameron, A.; Konforte, D. AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 EUA and LDT Serologic Testing in Clinical Laboratories. Clin. Chem. 2021. [CrossRef]

108. Guo, L.; Ren, L.; Yang, S.; Xiao, M.; Chang, D.; Yang, F.; Cruz, C.S.D.; Wang, Y.; Wu, C.; Xiao, Y.; et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin. Infect. Dis. 2020, 71, 778–785. [CrossRef] [PubMed]

109. Lynch, K.L.; Whitman, J.D.; Lacanienta, N.P.; Beckerdite, E.W.; Kastner, S.A.; Shy, B.R.; Goldgof, G.M.; Levine, A.G.; Bapat, S.P.; Reimerink, J. Differences in Antibody Kinetics and Functionality between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections. J. Infect. Dis. 2020, 222, 301–308. [CrossRef]

110. Rijkers, G.; Murk, J.-L.; Wintermans, B.; Van Looy, B.; Berge, M.V.D.; Veenemans, J.; Stohr, J.; Reusken, C.; Van Der Pol, P.; Reimerink, J. Differences in Antibody Kinetics and Functionality between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections. J. Infect. Dis. 2020, 222, 1265–1269. [CrossRef] [PubMed]

111. Gudbjartsson, D.F.; Norddahl, G.L.; Melsted, P.; Gunnarsdottir, S.; Holm, H.; Eythorsson, E.; Arnthorsson, A.O.; Helgason, D.; Bjarnadottir, K.; Ingvarsson, K.; et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N. Engl. J. Med. 2020, 383, 1724–1734. [CrossRef] [PubMed]

112. Liu, G.; Rusling, J.F. COVID-19 Antibody Tests and Their Limitations. ACS Sens. 2021, 6, 593–612. [CrossRef]

113. Interim Guidelines for COVID-19 Antibody Testing. Available online: https://www.cdc.gov/coronavirus/2019-n cov/lab/resources/antibody-tests-guidelines.html (accessed on 30 March 2021).

114. The National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: A head-to-head benchmark comparison. Lancet Infect. Dis. 2020, 20, 1390–1400. [CrossRef]

115. Pérez-García, F.; Pérez-Tanoira, R.; Iglesias, M.E.; Romanyk, J.; Arroyo, T.; Gómez-Herruz, P.; González, R.; García, S.L.; Cuadros-González, J. Comparative evaluation of six immunoassays for the detection of antibodies against SARS-CoV-2. J. Virol. Methods 2021, 289, 114047. [CrossRef]

116. Nilsson, A.C.; Holm, D.K.; Justesen, U.S.; Gorm-Jensen, T.; Andersen, N.S.; Øvrehus, A.; Johansen, I.S.; Michelsen, J.; Sprogøe, U.; Lillevang, S.T. Comparison of six commercially available SARS-CoV-2 antibody assays—Choice of assay depends on intended use. Int. J. Infect. Dis. 2021, 103, 381–388. [CrossRef]

117. Padoan, A.; Bonfante, F.; Pagliari, M.; Bortolami, A.; Negrini, D.; Zuin, S.; Bozzato, D.; Cosma, C.; Sciacovelli, L.; Plebani, M. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine 2020, 62, 103101. [CrossRef]
118. Whitman, J.D.; Hiatt, J.; Mowery, C.T.; Shy, B.R.; Yu, R.; Yamamoto, T.N.; Rathore, U.; Goldgof, G.M.; Whitty, C.; Woo, J.M.; et al. Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. *Nat. Biotechnol.* 2020, 38, 1174–1183. [CrossRef] [PubMed]

119. Nirimidas Biotech, Inc. *MidaSpotTM COVID-19 Antibody Combo Detection Kit: Instructions for Use*; Nirimidas Bio-tech, Inc.: Palo Alto, CA, USA, 2020. Available online: https://www.fda.gov/media/144877/download (accessed on 21 June 2021).

120. Clarity Diagnostics, LLC. *Sienna-Clarity COVIBLOCK COVID-19 IgG/IgM Rapid Test Cassette: Instructions for Use*; Clarity Diagnostics, LLC.: Boca Raton, FL, USA, 2020. Available online: https://www.fda.gov/media/140882/download (accessed on 21 June 2021).

121. Healgen Scientific, LLC. *COVID-19 IgG/IgM Rapid Test Cassette: Instructions for Use*; Healgen Scientific, LLC: Houston, TX, USA, 2020. Available online: https://www.fda.gov/media/138438/download (accessed on 21 June 2021).

122. Sugentech, Inc. *SGTI-flux COVID-19 IgG Test: Instructions for Use*; Sugentech, Inc.: Daejeon, Korea, 2020. Available online: https://www.fda.gov/media/141891/download (accessed on 21 June 2021).

123. Symbiotic, Inc. *COVID-19 Antibody Combo Detection Kit: Emergency Use Authorization Summary*; Symbiotic, Inc.: Vacaville, CA, USA, 2020. Available online: https://www.fda.gov/media/147365/download (accessed on 21 June 2021).

124. Kantaro Biosciences, LLC. *COVID-SeroKlir, Kantaro Semi-Quantitative SARS-CoV-2 IgG Antibody Kit: Emergency Use Authorization Summary*; Kantaro Biosciences, LLC.: New York, NY, USA, 2020. Available online: https://www.fda.gov/media/144010/download (accessed on 21 June 2021).

125. GenScript USA, Inc. *cP ASS SARS-CoV-2 Neutralization Antibody Detection Kit: Instructions for Use*; GenScript USA, Inc.: Piscataway, NJ, USA, 2020. Available online: https://www.fda.gov/media/143583/download (accessed on 21 June 2021).

126. ZEUS Scientific, Inc. *ZEUS ELISA SARS-CoV-2 IgG Test System: Instructions for Use*; ZEUS Scientific, Inc.: Branchburg, NJ, USA, 2020. Available online: https://www.fda.gov/media/142809/download (accessed on 21 June 2021).

127. Mount Sinai Laboratories. *COVID-19 ELISA IgG Antibody Test: Emergency Use Authorization Summary*; Mount Sinai Lab: New York, NY, USA, 2020. Available online: https://www.fda.gov/media/137029/download (accessed on 21 June 2021).

128. Siemens Healthcare Diagnostics, Inc. *Dimension EXL SARS-CoV-2 IgG Test: Instructions for Use*; Siemens Healthcare Diagnostics: Newark, DE, USA, 2020. Available online: https://www.fda.gov/media/138757/download (accessed on 21 June 2021).

129. Ortho-Clinical Diagnostics. *VITROS Immunodiagnostics Products Anti-SARS-CoV-2 Total Reagent Pack: Instructions for Use*; Ortho-Clinical Diagnostics: Raritan, NJ, USA, 2020. Available online: https://www.fda.gov/media/137363/download (accessed on 21 June 2021).

130. Roche Molecular Systems. *Elecsys Anti-SARS-CoV-2: Instructions for Use*; Roche Diagnostics: Indianapolis, IN, USA, 2020. Available online: https://www.fda.gov/media/140307/download (accessed on 21 June 2021).

131. Beckman Coulter, Inc. *Access SARS-CoV-2 IgM Test: Instructions for Use*; Beckman Coulter, Inc.: Brea, CA, USA, 2020. Available online: https://www.fda.gov/media/142911/download (accessed on 21 June 2021).

132. DiaSorin, Inc. *LIAISON SARS-CoV-2 S1/S2 IgG Test: Instructions for Use*; DiaSorin, Inc.: Stillwater, MN, USA, 2020. Available online: https://www.fda.gov/media/137359/download (accessed on 21 June 2021).

133. BioCheck, Inc. *BioCheck SARS-CoV-2 IgG Antibody Test Kit-Instructions for Use*; BioCheck, Inc.: South San Francisco, CA, USA, 2020. Available online: https://www.fda.gov/media/142006/download (accessed on 21 June 2021).

134. Vibrant America Clinical Labs. *Vibrant America Labs Vibrant COVID-19 Ab Kit: Emergency Use Authorization Summary*; Vibrant America Clinical Labs: San Carlos, CA, USA, 2020. Available online: https://www.fda.gov/media/138629/download (accessed on 21 June 2021).